News & Updates

Supplementation with resveratrol does not appear to provide much benefit in the management of cardiometabolic risk factors in patients with type 2 diabetes (T2D), metabolic syndrome (MetS), and nonalcoholic fatty liver disease (NAFLD), suggests a study.

The risk of hepatocellular carcinoma (HCC) among patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis is low, reveals a recent study. In addition, dose-dependent statin can substantially lower the risk of HCC in patients with NASH cirrhosis.

Burnout is experienced by nearly half (~40 percent) of hepatology providers during the COVID-19 pandemic, as shown by the negative impact of emotional well-being, including work fulfilment and satisfaction, according to a study.

Switching from tenofovir disoproxil fumarate (TDF) regimens to tenofovir alafenamide (TAF) monotherapy demonstrates long-term efficacy and safety in orthotopic liver transplantation (OLT) recipients with chronic hepatitis B virus (HBV) infection, reports a study presented at The Liver Meeting Digital Experience 2021, by the American Association for the Study of Liver Diseases (AASLD 2021).

The first human pharmacokinetic study of tenofovir alafenamide (TAF; commercially sold as Vemlidy) monotherapy in breastfeeding women with chronic hepatitis B (CHB) has found low concentrations of TAF and tenofovir in the breastmilk, with negligible exposure to infants.

A hepatitis C virus (HCV) micro-elimination programme targeting high-risk groups can enhance the effectiveness of screening and significantly shorten the time to starting direct-acting antiviral (DAA) therapy without compromising treatment outcomes, researchers at the University of Hong Kong (HKU) have reported.

Higher intake of alcohol and reduced care during the COVID-19 pandemic have triggered a spike in alcohol-related liver diseases, leading to some serious consequences, according to new research.

Namodenoson, an A3 adenosine receptor (A3AR) agonist, shows clinical activity against nonalcoholic fatty liver disease (NAFLD) with or without nonalcoholic steatohepatitis (NASH), according to data from a phase II study.